Pirtobrutinib for the Treatment of Therapy-Resistant Chronic Lymphatic Leukemia With CNS Localization. (PubMed, Case Rep Hematol) - Oct 24, 2026 - "There are currently three cBTKis approved for treatment of CLL/SLL: acalabrutinib, ibrutinib, and zanubrutinib. Pirtobrutinib appears to be effective in patients with ibrutinib resistance, even with CNS localization. Clinical responses may take several months to become evident."
Journal • Chronic Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Oncology
|
|
A P Kater; E van der Spek; M E Roerink; S H Tonino
|